Longhao Zhang
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
From the invasive front to organotropic pre-metastatic niches: spatial immune regulatory networks governing cholangiocarcinoma dissemination and metastasis-intercepting immunotherapy.
Journal: Frontiers in immunology
Published: June 25, 2026
Therapy-imprinted fibroblast memory in cholangiocarcinoma: rewiring CAF niches for immune evasion and treatment-resistant relapse.
Journal: Frontiers in immunology
Published: June 12, 2026
The Impact of Spatiotemporal Patterns of Tumor Recurrence on Prognosis in Hepatocellular Carcinoma Patients Undergoing Surgery After Conversion Therapy.
Journal: Journal of hepatocellular carcinoma
Published: February 07, 2026
A cystic lesion adjacent to the cystic duct diagnosed as ectopic thyroid tissue: a laparoscopic case report.
Journal: Frontiers in surgery
Published: November 21, 2025
Primary Hepatic Somatostatinoma (G2) With Diabetes and Nodal Metastasis: An Exceptionally Rare Primary Liver Tumor.
Journal: The American journal of gastroenterology
Published: November 18, 2025
Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment.
Journal: Frontiers in immunology
Published: September 01, 2025
Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy.
Journal: Signal transduction and targeted therapy
Published: July 31, 2025
PAFAH1B3 Exists in Linear Chromosomal and Extrachromosomal Circular DNA and Promotes HCC Progression via EMT.
Journal: International journal of molecular sciences
Published: June 24, 2025
Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies.
Journal: Frontiers in immunology
Published: June 22, 2025
Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.
Journal: Hepatology (Baltimore, Md.)
Published: April 29, 2025
Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: April 21, 2025
Last Updated: 09/26/2026